Imidacloprid: H113-7/2001-11E

This regulatory note provides a summary of decisions taken and the rationales for the regulatory decisions regarding these products. The ongoing assessment of data, including studies generated in Canada, has confirmed the inherent properties of imidacloprid as identified in the original assessment and supports the continued judicious approach taken by the PMRA to use expansions to the imidacloprid use pattern.--Page 1
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.615755&sl=0
| Department/Agency |
|
|---|---|
| Title | Imidacloprid |
| Series title |
|
| Publication type | Monograph - View Master Record |
| Language | [English] |
| Other language editions | [French] |
| Format | Physical text |
| Other formats | Digital text-[English] |
| Note(s) |
|
| Publishing information |
|
| Binding | Softcover |
| Description | 10p. : tables ; 28 cm. |
| ISBN | 0-662-31036-5 |
| Catalogue number |
|
| Subject terms |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.Page details
- Date modified: